Views
5 years ago

Bases biológicas y targets

  • Text
  • Renal
  • Cardiacas
  • Ventricular
  • Cardiaca
  • Diastolica
  • Celulares
  • Fibrinolisis
  • Coagulacion
  • Plaquetaria
  • Arterial
  • Homeostaticos
  • Cardiaca
  • Insuficiencia
Farmacología Cardiovascular - De la molécula al paciente. Bases biológicas y targets en la terapéutica cardiovascular

EM Ylarri //

EM Ylarri // Señalización intracelular e interrelación de sistemas homeostáticos en patología cardiovascular Lecturas sugeridas • Androulakis ES1, Tousoulis D, Papageorgiou N et al. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev 2009;17:216-21. • Berridge MJ Unlocking the secrets of cell signaling. Annu Rev Physiol. 2005;67:1–21. • Catena C, Colussi G, Marzano L et al. Aldosterone and the Heart: From Basic Research to Clinical Evidence. Horm Metab Res 2012;44:181–187. • Diz DI, Arnold AC, Nautiyal M, et al. Angiotensin peptides and central autonomic regulation. Curr Opin Pharmacol. 2011;11131-7. • Felder RB, Yu Y; Zhang ZH et al. Pharmacological Treatment for Heart Failure: A View From the Brain. Clin Pharmacol Ther. 2009;86:216–220. • Ferrario CM, Strawn WB. Targeting the RAAS for the treatment of aterosclerosis. Drug Discov Today 2005;2:221-9. • Gajjala PR, Sanati M and Jankowski J. Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities. Front Immunol. 2015:6:Art 340. • Hopps E and Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 2015;19:2583-2589. • Liehn EA, Postea O, Curaj A et al. Repair After Myocardial Infarction, Between Fantasy and Reality. The Role of Chemokines J Am Coll Cardiol 2011;58:2357–62. • Rockey DC, Bell D and Hill JA. Fibrosis - A Common Pathway to Organ Injury and Failure. N Engl J Med 2015;372:1138-49. • Ruschitzka F, Corti R, Noll G el al. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999 Feb;17(1):S25-35. • Savoia C and Schiffrin E. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical Science 2007;112:375–384. • Suzuki Y, Ruiz-Ortega M, Lorenzo O et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003:35:881–900. • Triposkiadis F, Karayannis G, Giamouzis G et al. The Sympathetic Nervous System in Heart Failure Physiology, Pathophysiology, and Clinical Implications. J Am Coll Cardiol 2009;54:1747–62. • Vaneckova I, Maletınska L, Behuliak M et al. Obesity-related hypertension: possible pathophysiological mechanisms. Journal of Endocrinology 2014;223, R63–R78. • Yoshimoto T, Naruse M, Tanabe A et al. Potentiation of Natriuretic Peptide Action by the b-Adrenergic Blocker Carvedilol in Hypertensive Rats:A New Antihypertensive Mechanism. Endocrinology 1998;139:81– 881998. • Zhang W and Mifflin S. Plasticity of GABAergic Mechanisms Within the Nucleus of the Solitary Tract in Hypertension Hypertension 2010;55;201-206. EDITORIAL SCIENS 47

EM Ylarri // Farmacología cardiovascular. De la molécula al paciente. Bases biológicas y targets en la terapéutica cardiovascular 48

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015